ProPhase Labs Inc (PRPH) - Total Assets
Based on the latest financial reports, ProPhase Labs Inc (PRPH) holds total assets worth $65.70 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PRPH book value for net asset value and shareholders' equity analysis.
ProPhase Labs Inc - Total Assets Trend (1996–2024)
This chart illustrates how ProPhase Labs Inc's total assets have evolved over time, based on quarterly financial data.
ProPhase Labs Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ProPhase Labs Inc's total assets of $65.70 Million consist of 48.5% current assets and 51.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.1% |
| Accounts Receivable | $20.06 Million | 31.7% |
| Inventory | $1.14 Million | 1.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.75 Million | 15.4% |
| Goodwill | $5.23 Million | 8.3% |
Asset Composition Trend (1996–2024)
This chart illustrates how ProPhase Labs Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRPH company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProPhase Labs Inc's current assets represent 48.5% of total assets in 2024, a decrease from 71.4% in 1996.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2024, down from 28.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, a decrease from 28.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 31.7% of total assets.
ProPhase Labs Inc Competitors by Total Assets
Key competitors of ProPhase Labs Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
INTERGRATED DIA.H DL 025
F:8I8
|
Germany | €6.77 Billion |
|
Immunovia publ AB
ST:IMMNOV
|
Sweden | Skr88.21 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €685.34K |
|
Wellfully Ltd
AU:WFL
|
Australia | AU$3.51 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
ProPhase Labs Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.14 | 1.47 | 2.52 |
| Quick Ratio | 0.14 | 1.33 | 2.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-47.51 Million | $13.54 Million | $9.59 Million |
ProPhase Labs Inc - Advanced Valuation Insights
This section examines the relationship between ProPhase Labs Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.08 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $63.20 Million |
| Market Capitalization | $515.86K USD |
Valuation Analysis
Below Book Valuation: The market values ProPhase Labs Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ProPhase Labs Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProPhase Labs Inc (1996–2024)
The table below shows the annual total assets of ProPhase Labs Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $63.20 Million | -31.25% |
| 2023-12-31 | $91.93 Million | +4.88% |
| 2022-12-31 | $87.65 Million | -1.84% |
| 2021-12-31 | $89.30 Million | +184.33% |
| 2020-12-31 | $31.41 Million | +155.87% |
| 2019-12-31 | $12.27 Million | -40.81% |
| 2018-12-31 | $20.74 Million | -39.30% |
| 2017-12-31 | $34.16 Million | +166.84% |
| 2016-12-31 | $12.80 Million | -13.67% |
| 2015-12-31 | $14.83 Million | -7.65% |
| 2014-12-31 | $16.06 Million | -7.82% |
| 2013-12-31 | $17.42 Million | +4.56% |
| 2012-12-31 | $16.66 Million | -12.67% |
| 2011-12-31 | $19.08 Million | -12.06% |
| 2010-12-31 | $21.70 Million | +9.48% |
| 2009-12-31 | $19.82 Million | -18.68% |
| 2008-12-31 | $24.37 Million | -26.85% |
| 2007-12-31 | $33.31 Million | -4.39% |
| 2006-12-31 | $34.85 Million | -3.14% |
| 2005-12-31 | $35.98 Million | +14.10% |
| 2004-12-31 | $31.53 Million | +20.02% |
| 2003-12-31 | $26.27 Million | +5.35% |
| 2002-12-31 | $24.93 Million | +0.72% |
| 2001-12-31 | $24.76 Million | -4.99% |
| 2000-12-31 | $26.06 Million | -21.75% |
| 1999-12-31 | $33.30 Million | -31.48% |
| 1998-12-31 | $48.60 Million | -2.41% |
| 1997-12-31 | $49.80 Million | +3457.14% |
| 1996-12-31 | $1.40 Million | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more